首页> 外文期刊>The Journal of Pathology: Clinical Research >Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients
【24h】

Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients

机译:数字病理学时代的组织微阵列的构建和分析:一项针对CDX1和CDX2的612名结肠癌队列研究

获取原文
       

摘要

Abstract CDX1 and CDX2 are possibly predictive biomarkers in colorectal cancer. We combined digitally-guided (next generation) TMA construction (ngTMA) and the utility of digital image analysis (DIA) to assess accuracy, tumour heterogeneity and the selective impact of different combined intensity-percentage levels on prognosis.CDX1 and CDX2 immunohistochemistry was performed on ngTMAs covering normal tissue, tumour centre and invasive front. The percentages of all epithelial cells per staining intensity per core were analysed digitally. Beyond classical prognosis analysis following REMARK guidelines, we investigated pre-analytical conditions, three different types of heterogeneity (mosaic-like, targeted and haphazard) and influences on cohort segregation and patient selection. The ngTMA-DIA approach produced robust biomarker data with infrequent core loss and excellent on-target punching. The detailed assessment of tumour heterogeneity could ?¢???? except for a certain diffuse mosaic-like heterogeneity ?¢???? exclude differences between the invasive front and tumour centre, as well as detect haphazard clonal heterogeneous elements. Moreover, lower CDX1 and CDX2 counts correlated with mucinous histology, higher TNM stage, higher tumour grade and worse survival ( p < 0.01, all). Different protein expression intensity levels shared comparable prognostic power and a great overlap in patient selection. The combination of ngTMA with DIA enhances accuracy and controls for biomarker analysis. Beyond the confirmation of CDX1 and CDX2 as prognostically relevant markers in CRC, this study highlights the greater robustness of CDX2 in comparison to CDX1. For the assessment of CDX2 protein loss, cut-points as percentage data of complete protein loss can be deduced as a recommendation.
机译:摘要CDX1和CDX2可能是结直肠癌的预测生物标志物。我们结合了数字引导(下一代)TMA构建(ngTMA)和数字图像分析(DIA)的实用性,以评估准确性,肿瘤异质性以及不同组合强度百分比水平对预后的选择性影响。进行了CDX1和CDX2免疫组化涵盖正常组织,肿瘤中心和浸润前线的ngTMA上。数字分析每个核心每个染色强度中所有上皮细胞的百分比。除了遵循REMARK指南的经典预后分析外,我们还研究了分析前的状况,三种不同类型的异质性(马赛克样,靶向性和偶然性)以及对人群隔离和患者选择的影响。 ngTMA-DIA方法产生了可靠的生物标志物数据,很少出现核心损失,并且具有出色的靶向打孔效果。肿瘤异质性的详细评估可以除了一定的弥散性马赛克样异质性排除浸润前缘和肿瘤中心之间的差异,并检测偶然的克隆异质元素。此外,较低的CDX1和CDX2计数与粘液组织学,较高的TNM分期,较高的肿瘤等级和较差的生存率相关(p <0.01,全部)。不同的蛋白表达强度水平具有可比的预后能力,并且在患者选择上有很大的重叠。 ngTMA与DIA的结合可提高准确性和生物标记物分析的控制。除了证实CDX1和CDX2是CRC中与预后相关的标志物外,这项研究还强调了CDX2与CDX1相比具有更大的鲁棒性。为了评估CDX2蛋白质的损失,建议将临界点作为蛋白质完全损失的百分比数据推导出来。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号